Documentos de Académico
Documentos de Profesional
Documentos de Cultura
MSP
MSP
DR
HARISUTHAN.T
Overview
Multisystem proteinopathy (MSP) is an inherited pleiotropic degenerative
disorder that can affect muscle, bone, and the nervous system and was first
reported as familial motor neuron disease in association with Paget disease of
bone (PDB).
The MSP phenotype also involves inclusion body myopathy (IBM) or
frontotemporal dementia (FTD).
Since the original description, various reports of families with IBMPFD have
made some reference to ALS, either explicitly (e.g., by the mention of family
member with ALS) or implicitly (e.g., through clinical and electrophysiologic
findings that indicate motor neuron involvement, such as fasciculations,
spasticity, hyperreflexia, extensor plantar responses, chronic reinnervation
changes on EMG, and prolonged central motor conduction time).
Invariably, these reports overlooked the possible direct connection between
VCP mutations and ALS.
Clinical Features
Tucker et al. (1982) studied a large kindred with a syndrome of
lower motor neuron degeneration and polyostotic skeletal
disorganization resembling Paget disease of bone.
The disorder begins insidiously at about age 35 with weakness
and atrophy of the leg and proximal arm muscles.
Nerve conductions are normal; EMG shows muscle denervation,
as does muscle biopsy.
Kimonis et al. (2000) described a family in which autosomal dominant limbgirdle muscular dystrophy (LGMD) was associated with early-onset Paget
disease of bone PDB and cardiomyopathy.
Eight of 11 affected individuals had both disorders.
Onset of PDB occurred at a mean age of 35 years, with classic distribution
involving the spine, pelvis, and skull.
Muscle weakness and atrophy was progressive with mildly elevated to normal
CPK levels.
Kim et al. (2011) reported 3 Korean sibs with IBMPFD confirmed by genetic
analysis. The proband developed progressive dementia presenting as fluent
aphasia and language difficulties with onset at age 47.
She never developed myopathy, but did develop asymptomatic Paget disease
with increased serum alkaline phosphatase and lytic bone lesions on imaging.
Her brother developed slowly progressive proximal muscle weakness at age 50,
followed by frontotemporal dementia characterized initially by comprehension
defects at age 54. He never had Paget disease, although serum alkaline
phosphatase was increased.
Watts et al. (2004) reported 13 families with IBMPFD, 12 from the U.S.
and 1 from Canada. Among those individuals, 82% of affected
individuals had myopathy, 49% had PDB, and 30% had early-onset
frontotemporal dementia.
The mean age at presentation was 42 years for both IBM and PDB,
whereas frontotemporal dementia typically presented at age 53 years.
In IBMPFD myopathic muscle and PDB osteoclasts, inclusions appear
similar, suggestive of disruptions in the same pathologic pathway.
Nature Genet. 36: 377-381, 2004.
Viassolo et al. (2008) reported an Italian family in which 2 sibs and their
mother had IBMPFD. All 3 had progressive inclusion body myopathy and
rapidly progressive severe dementia, but only 1 developed Paget disease.
Genetic analysis identified a heterozygous mutation in the VCP gene. Several
other family members were reportedly affected.
Viassolo et al.(2008) discussed the implications of the incomplete penetrance
of some of the features for genetic counseling.
Neuropathologic Findings
Schroder et al. (2005) reported a patient with frontotemporal dementia (FTD) and
inclusion body myopathy caused by mutation in the VCP gene. There was no
evidence of Paget disease. Neuropathologic examination showed cortical atrophy
and widespread neuronal loss; subcortical neuronal loss was less severe.
The cerebral and cerebellar white matter had severe astrogliosis. Surviving
cortical pyramidal neurons contained VCP- and ubiquitin - positive intranuclear
inclusions and displayed cytoplasmic autofluorescence consistent with lipofuscin.
Histopathologically,
Disease-causing mutations in VCP provided the first insight into the molecular etiology of
MSP, accounting for up to 50% of families with this genetically heterogeneous syndrome.
Mutations in HNRNPA2B1 and HNRNPA1 were subsequently identified in families with MSP
that was clinically and histopathologically indistinguishable from VCP mutation cases.
These discoveries prompted recognition that rare pathogenic genetic mutations are
lurking in larger populations of patients with more common MSP-related diseases, such as
ALS and FTD.
For example, mutations in VCP, HNRNPA1, and HNRNPA2B1 have been identified in
sporadic and familial forms of ALS.
Bucelli et al. report the identification of disease-causing mutations in SQSTM1 in a family with an
autosomal dominant IBM that clinically and histopathologically closely resembles that seen in
association with VCP, HNRNPA2B1, and HNRNPA1 mutations.
The pattern of muscle weakness was that of a distal or facioscapulo distal myopathy, and the
muscle pathology demonstrated rimmed vacuoles as well as inclusions of both TDP-43 and SQSTM1.
Pathogenic mutations in SQSTM1 are a frequent cause of PDB and are responsible for rare cases of
sporadic and familial ALS and FTD.
Mutations in SQSTM1 are now associated with pleiotropic clinical features that include myopathy,
dementia, motor neuron disease, and PDB and should, be included among the MSPs.
found in each protein that mediates the assembly of RNA granules, specialized cytoplasmic RNA
protein assemblies that control posttranscriptional messenger RNA metabolism. The
consequence of disease mutations is excess assembly and persistence of RNA granules,
probably accounting for accumulation of granule components in pathologic inclusions.
This disturbance of RNA granule dynamics likely alters RNA metabolism and probably
contributes to disease pathogenesis.
Conclusion
IBMPFD presents as a multisystem disorder affecting brain, skeletal and
cardiac muscle, spinal cord and bone.
Clinical reports of this disease are scarce.
Family members usually presented with proximal weakness, progressing to
wheelchair disability and premature death.
The R155H mutation, an arginine-to-histidine substitution in the N-terminal
CDC48 domain of the VCP protein, results in loss of VCP function and is found
exclusively in individuals affected with IBMPFD.
Second, what can we learn from MSP about the etiologic relationship
between seemingly distinct age-related degenerative diseases of muscle,
bone, and brain?
The current evidence suggests that subsets of patients with ALS, FTD, IBM,
and PDB share a common molecular pathogenesis related to the
metabolism of RNA granules and their destruction by autophagy.
Thus, therapeutic development for restoring RNA granule homeostasis, socalled ribostasis, may apply to a broad spectrum of age-related
degenerative diseases.
Thank you